Disodium inosinate

Disodium Inosinate (E631 / IMP)

1. Identity and Chemical Characterization

Names and Classification

Disodium inosinate (E631) is the disodium salt of inosinic acid, with the chemical formula C₁₀H₁₁N₄Na₂O₈P. It is also known as disodium 5′-inosinate or IMP (inosinate monophosphate), and it is a naturally occurring nucleotide compound with the CAS number 4691-65-0. It is a nucleoside monophosphate, meaning it consists of a nucleoside (inosine) linked to a single phosphate group. IMP is the ribonucleotide of hypoxanthine and serves as a precursor for other important molecules. In European food additive nomenclature it carries the number E631. Its related free acid, inosinic acid, bears the number E630; closely related salts include dipotassium inosinate (E632) and calcium inosinate (E633).

Physical Form and Preparations

IMP is a white granular or powder, commonly combined with another flavour enhancer, disodium guanylate (GMP), as disodium 5′-ribonucleotides (E635), or with monosodium glutamate (MSG). Both GMP and IMP are supplied as odorless, colorless — or white — crystals, or as a white powder. They are soluble in water. The crystalline commercial form is the heptahydrate salt; the FDA specifies that disodium inosinate must be manufactured and purified so as to contain no more than 150 parts per million of soluble barium in the compound disodium inosinate with seven and one-half molecules of water of crystallization.

Natural Sources

Inosine monophosphate occurs naturally in various foods, particularly in meat, fish, and some vegetables. It contributes to the savory taste known as umami. In meat, IMP is the most abundant 5′-ribonucleotide and is known to impart an umami taste. Disodium inosinate is found naturally in beef, pork, chicken, and many common fish including sea bass, tuna, and others. Red meat, pork, fish, and poultry products are rich inosine sources, and IMP's 5′-monophosphate is associated with the flavor and taste of red and white meats. Inosine-5′-monophosphate (I-5-MP) is widely distributed in nature and has been demonstrated in liver, tumor cells, and microorganisms. IMP is widely distributed in all tissues of animals and plants.

Commercial Production

Commercial disodium inosinate may either be obtained from bacterial fermentation of sugars or prepared from animal products. The Vegetarian Society reports that production from meat or fish is more widespread, but the Vegetarian Resource Group reports that all three "leading manufacturers" claim to use fermentation. This additive is produced through fermentation processes, often using microbial sources like yeast or bacteria on substrates such as tapioca starch or sugar, followed by extraction and neutralization with sodium hydroxide to form the disodium salts. Methods of preparing IMP include a method of enzymatically degrading ribonucleic acids which are extracted from yeast cells, and a method of chemically phosphorylating inosine which is produced by fermentation. In more recent industrial practice, IMP is produced by fermentation using strains of Corynebacterium stationis, yielding the disodium salt of inosine 5′-monophosphate.

The Combined Additive "I+G" (E635)

Disodium 5′-ribonucleotides, also known as E635 or I+G, is a widely used food additive that functions as a flavor enhancer by intensifying the umami taste, particularly when combined synergistically with glutamates such as MSG. It consists of a mixture of disodium inosinate (IMP) and disodium guanylate (GMP) in roughly equal proportions, typically 47–53% each on an anhydrous basis. The flavor-enhancing strength of the combination of 98% MSG with 2% I+G is around four times that of monosodium glutamate (MSG) alone.

2. Traditional and Historical Use

East Asian Culinary Traditions

Dried bonito has been used to make dashi in Japan for a long time. In 1913, Kodama, who was the best pupil of Ikeda, found that the active principle of dried bonito is 5′-inosinate (salt of 5′-inosinic acid). This scientific identification formalized what Japanese cooks had practiced empirically for centuries: the preparation of dashi, a soup stock combining konbu (kelp, rich in glutamate) with katsuobushi (dried, fermented skipjack tuna flakes, rich in IMP). The phenomenon of umami synergism is widely recognized and practiced worldwide through combinations such as konbu with dried bonito in dashi, or by mixing vegetables and meat or fish in various soup stocks. This traditional practice of combining glutamate-rich ingredients with IMP-rich ingredients, whether in Japanese dashi, European meat stocks, or Chinese cuisine, constitutes the historical application of what is now understood as disodium inosinate's flavor-enhancing activity.

Scientific Identification and Commercialization

In 1908, Kikunae Ikeda identified the unique taste component of konbu (kelp) as the salt of glutamic acid and coined the term umami to describe this taste. Ikeda's protégé Shintaro Kodama undertook this project and in 1913 identified 5′-inosinate (salt of inosine-5′-monophosphate) as the umami taste in bonito. Ikeda's protégé Kodama continued his work, identifying the umami component in bonito flakes (skipjack tuna flakes), which in 1913 he identified as 5′-inosinate. Much later, in 1957, Kuninaka found that 5′-guanylate has umami taste; later it was found to be a component in shiitake mushrooms.

Akira Kuninaka also found that the taste intensity of umami was greatly enhanced by mixing of MSG and 5′-ribonucleotides, the phenomenon known as umami synergism (Kuninaka, 1960). In 1985, the term umami was recognized as the scientific term to describe the taste of glutamates and nucleotides at the first Umami International Symposium in Hawaii.

Commercialization of disodium inosinate, the sodium salt of IMP, began in the 1960s with industrial production pioneered by Ajinomoto Co., which launched its sodium inosinate product in 1964 through bacterial fermentation processes, paralleling the earlier development of MSG. These efforts transitioned from lab-scale animal extractions to scalable methods, enabling early incorporation into food products to amplify umami in seasonings and processed Japanese cuisine.

3. Biochemistry: Key Constituents and Mechanisms of Action

The IMP Molecule and Purine Biochemistry

Inosine 5′-monophosphate (5′-IMP) is an essential nucleotide for de novo nucleotide biosynthesis and metabolism of energy, proteins, and antioxidants. IMP plays a critical role in the biosynthesis of purines and serves as a key intermediate in the metabolism of nucleotides. It is formed from the conversion of ribose-5-phosphate and serves as a precursor for both adenosine monophosphate (AMP) and guanosine monophosphate (GMP), linking it directly to the purine nucleotide cycle.

The de novo pathway of purine synthesis is complex, consisting of 11 steps and requiring six molecules of ATP for every purine synthesized. The precursors that donate components to produce purine nucleotides include glycine, ribose-5-phosphate, glutamine, aspartate, carbon dioxide, and N10-formyltetrahydrofolate. Purines are synthesized as ribonucleotides, with the initial purine synthesized being inosine monophosphate (IMP). Adenosine monophosphate (AMP) and guanosine monophosphate (GMP) are each derived from IMP in two-step reactions.

Inosine monophosphate holds a central position in the body's purine metabolism, acting as a key intermediate in both the synthesis and breakdown pathways of purines. Inosinate takes part in regulating purine nucleotide biosynthesis. It is the first nucleotide formed during purine metabolism. In the catabolic pathway it is converted into uric acid and is excreted from the body.

IMP in the Purine Nucleotide Cycle and Muscle Metabolism

Conversion of AMP to inosine monophosphate via adenylate deaminase and then to adenylosuccinate helps sustain the myokinase reaction, especially in fast-glycolytic fibers, by reducing accumulation of AMP. It may also reduce the loss of adenosine from the cell, since nucleosides permeate cell membranes whereas nucleotides do not. Nucleotides are conditionally essential, as they cannot be produced sufficiently rapidly to meet the needs of the body in situations of oxidative stress or rapid muscle growth. A deficient intake of nucleotides can result in decreased ATP and GTP synthesis and impaired metabolism.

Metabolic Catabolism of IMP

The purine catabolism pathway proceeds: AMP → IMP → Inosine → Hypoxanthine → Xanthine → Uric Acid. Hypoxanthine and xanthine are converted to the terminal product of purine catabolism, uric acid, by the enzyme xanthine oxidase. IMP is widely distributed in all tissues of animals and plants. Its role in purine metabolism as well as its breakdown to uric acid and to allantoin (in mammals except for primates) is well known. Because humans lack uricase, the terminal product in human purine catabolism is uric acid rather than the more soluble allantoin.

The compound is readily metabolized in the body to inosine and further to other nucleotide metabolites that are normally present in human metabolism.

4. Mechanism of Taste Action: Umami Synergism

Taste Receptors Involved

Umami taste is elicited by L-glutamate and some other amino acids, and is thought to be initiated by G-protein-coupled receptors. Proposed umami receptors include heterodimers of taste receptor type 1, members 1 and 3 (T1R1 + T1R3), and metabotropic glutamate receptors 1 and 4 (mGluR1 and mGluR4).

T1R1 + T1R3 exhibits a synergism between glutamate and 5′-inosinate or 5′-guanylate, but mGluR1 and mGluR4 do not exhibit the synergism. Key residues for the mouse-type broad response are located at regions outside of both the orthosteric ligand binding site and the allosteric binding site for inosine-5′-monophosphate (IMP), a known natural umami taste enhancer. IMP, previously known to potentiate umami taste, binds to a site of TAS1R1-VFT (Venus Flytrap domain) adjacent to the L-glutamate site, leading to umami synergy.

In rats, the response to a mixture of glutamate and 5′-inosinate is about 1.7 times larger than that to glutamate alone. In humans, the response to the mixture is about 8 times larger than that to glutamate alone. Since glutamate and 5′-inosinate are contained in various foods, we taste umami induced by the synergism in daily eating.

IMP and the Sweet Taste Receptor

Cellular assays revealed that IMP is able, like cyclamate, to modulate the response of TAS1R2/TAS1R3 and TAS1R3 alone when stimulated by calcium ions. IMP also acted as an enhancer of TAS1R2/TAS1R3 when stimulated with sucralose, neotame, and cyclamate. These data demonstrated that IMP modulates sweet compound detection at the receptor level via the TAS1R3 subunit. This is a relatively recent and still-emerging finding at the molecular biology level.

Concentration and Threshold Effects

The detection threshold for IMP (as a disodium salt) is in the same range as that for MSG, but unlike MSG, its value is affected by the presence of Na+. Mixtures of MSG plus IMP or GMP are synergistic, that is, capable of reciprocal increases in sensitivity. Subthreshold concentrations of IMP lower the detection threshold for MSG taste by nearly 100-fold, and conversely, the threshold of IMP is lowered by MSG.

5. Scientific Evidence by Area of Use

5.1 Umami Taste Enhancement and Flavor Perception

The most extensively documented function of disodium inosinate is as a flavor enhancer in the umami taste modality.

Human neuroimaging evidence: Umami taste stimuli, of which an exemplar is monosodium glutamate (MSG), were shown using functional MRI (fMRI) to activate similar cortical regions of the human taste system to those activated by a prototypical taste stimulus, glucose. These taste regions included the insular/opercular cortex and the caudolateral orbitofrontal cortex. A part of the rostral anterior cingulate cortex (ACC) was also activated. When the nucleotide 0.005 M inosine 5′-monophosphate (IMP) was added to MSG (0.05 M), the blood oxygenation-level dependent (BOLD) signal in an anterior part of the orbitofrontal cortex showed supralinear additivity; this may reflect the subjective enhancement of umami taste that has been described when IMP is added to MSG.

Umami compounds like MSG and inosine monophosphate (IMP) elicit stronger responses in the orbitofrontal cortex (OFC) and a distinct hedonic encoding in the dorsal anterior cingulate cortex compared to sweet or salty tastes, with synergistic umami mixtures producing supra-linear activation not observed in other taste modalities.

Evidence strength: Human fMRI evidence for the synergistic cortical representation of IMP+MSG combinations is well-established. The receptor-level mechanism (T1R1+T1R3) has been confirmed in heterologous expression systems and knock-out animal studies. Psychophysical data in humans are robust. This area represents the strongest body of evidence for IMP's primary use.

5.2 Sodium Reduction Strategy

An emerging area of human study is the use of IMP+MSG combinations to enhance perceived saltiness, thereby permitting reduction in total sodium content of foods.

A two-sip time-intensity (TI) analysis with trained panellists found that tasting MSG and IMP either simultaneously or successively enhanced saltiness perception at equal sodium concentrations. These findings indicate that the synergistic effect of umami substances may be the cause of saltiness enhancement, and represents a potential strategy for sodium reduction while satisfying the consumer demand for saltiness perception.

The synergistic umami effect represents a potential approach to salt reduction. Umami substances have the potential to enhance the perception of saltiness and thus reduce sodium intake.

Evidence strength: Evidence is preliminary and primarily from sensory science studies using trained panels. Large-scale controlled clinical trials examining actual sodium intake reduction, blood pressure outcomes, or cardiovascular endpoints using IMP specifically have not been identified in the peer-reviewed literature at this time. This remains a promising but not yet clinically validated area.

5.3 IMP in Meat Quality and Post-Mortem Biochemistry

IMP was the most abundant nucleotide in meat known to impart umami taste, which thus far had been overlooked in meat flavor studies. Research has sought to determine the umami taste threshold of inosine 5′-monophosphate (IMP), the effects of spiking IMP on the sensory descriptive attributes of various USDA-graded beef strip steaks, and methods to differentiate beef by IMP content.

Inosine and hypoxanthine are produced once IMP is degraded. Inosine is a tasteless substance, but hypoxanthine has a bitter taste. IMP and GMP decreased with increasing hypoxanthine during post-mortem aging, which is consistent with previous studies. This has practical implications for meat quality assessment, as IMP content at slaughter is a marker of freshness and flavor potential, and its degradation to tasteless and bitter compounds during storage is used as an index of meat quality decline.

Evidence strength: This is well-established food science, supported by analytical and sensory studies. It is not a human health or clinical endpoint.

5.4 Animal Studies: Growth, Energetics, and Antioxidant Status

Supplementation of finishing pig diets with 5′-IMP reduces the relative weight of the liver and increases oxygen consumption during mitochondrial respiration without changing the ADP/O ratio, indicating an increase in the respiratory efficiency of liver mitochondria. A reduction in liver lipid peroxidation and an increase in muscle creatine was also observed. Moreover, 5′-IMP supplementation increases slaughter weight, lean meat yield, sarcomere length, and backfat thickness in finishing barrows, demonstrating influence on protein metabolism.

Evidence strength: These are animal studies only (pigs). No equivalent human clinical trials assessing IMP supplementation on muscle mass, energy metabolism, or antioxidant status have been identified in the literature at this time. Findings cannot be extrapolated directly to humans.

5.5 IMP in Nucleotide Nutrition and Immune Function

Inosine monophosphate also plays a role in modulating the immune system. Its presence in breast milk and infant formula supports early growth and development. Breast milk contains various bioactive factors, including nucleotides like IMP, which aid in the development and functioning of the immune system in newborns.

Nucleotides have the basic biological function of encoding genetic information and mediating energy metabolism. Under normal conditions, de novo nucleotide synthesis is generally sufficient to support growth; therefore, nucleotides have traditionally been considered nonessential nutrients. However, dietary nucleotide deficiency may impair liver, heart, intestine, and immune functions.

Evidence strength: Most evidence for IMP's immunomodulatory role derives from animal studies and studies on mixed nucleotide formulations (not IMP in isolation). Human clinical evidence for immune benefits from supplemental IMP specifically is very limited and cannot be considered established.

6. Body Systems and Health Areas of Association

• Gustatory / Taste System: Since umami has its own receptors rather than arising out of a combination of the traditionally recognized taste receptors, scientists now consider umami to be a distinct taste. IMP is a direct ligand at the T1R1+T1R3 heterodimer, the primary human umami taste receptor.
• Purine Metabolism / Uric Acid System: E631 (disodium inosinate) is a purine nucleotide that is ultimately metabolised to uric acid. This metabolic pathway makes IMP biochemically relevant to gout and hyperuricemia.
• Energy Metabolism: IMP's levels and conversion are crucial for cellular energy and signaling processes. IMP is the central intermediate from which both ATP-precursor AMP and GTP-precursor GMP are synthesized.
• Skeletal Muscle: Conversion of AMP to inosine monophosphate via adenylate deaminase and then to adenylosuccinate helps sustain the myokinase reaction, especially in fast-glycolytic fibers, by reducing accumulation of AMP.
• Nucleic Acid Synthesis / Cell Proliferation: IMP acts as a precursor for both adenosine monophosphate (AMP) and guanosine monophosphate (GMP), which are critical for DNA and RNA synthesis.
• Neonatal Nutrition / Immune Development: IMP's presence in breast milk and infant formula supports early growth and development, with nucleotides like IMP aiding in the development and functioning of the immune system in newborns.

7. Food Additive Uses and Dosage Forms

Common Applications

Disodium inosinate is used as a food additive and often found in instant noodles, potato chips, and a variety of other snacks. It is used as a flavor enhancer in soups, sauces, and seasonings. IMP and guanosine monophosphate (GMP) are used together to enhance the meaty (umami) flavor of soups and other foods. They are often used together with MSG, because they enhance its potency.

The recommended levels of use of IMP in feed are in the range of the total nucleotide levels that may be present in feedstuffs like soybean meal and fish meal, which contain 38 and 75 mg of total nucleotides per kg, respectively. In the human food context, IMP is used in very small amounts by weight. Human data show that very high supplemental intakes of inosinate or related ribonucleotides can raise serum and urinary uric acid. Those dose levels are typically measured in grams per day and are far above what most people get from E631 as a flavour enhancer in foods.

In human sensory research, 0.005 M inosine 5′-monophosphate (IMP) added to 0.05 M MSG was used in fMRI studies demonstrating supralinear cortical activation. In animal growth studies, USDA Prime, Choice, and Select steaks were spiked with 0.3 and 0.6 mM IMP and analyzed chemically and organoleptically.

JECFA concluded that, on the basis of the available data, the combined total daily intake of disodium 5′-guanylate and disodium 5′-inosinate is not of toxicological significance, and re-confirmed the ADI "not specified." Because exposure to these substances from their use as flavour enhancers is low compared with daily intake of naturally occurring nucleotides in the diet, JECFA found no reason to recommend that foods to which these substances have been added should be labeled on the basis of safety.

8. Regulatory Status

United States (FDA)

In the US, disodium inosinate is permitted as a direct food additive under 21 CFR 172.535, used as a flavouring adjuvant in food, subject to the regulation's specifications and conditions. The food additive disodium inosinate may be safely used in food in accordance with specified conditions: it must be manufactured and purified so as to contain no more than 150 parts per million of soluble barium in the compound disodium inosinate with seven and one-half molecules of water of crystallization, and is used as a flavoring adjuvant in food.

European Union (EFSA / E631)

In the European Union, additives in the ribonucleotide group, including disodium inosinate identified as E631, are authorized under the consolidated food additive regulation, with permitted uses defined by food category and specific conditions of use. In the EU, E631 is authorised as a flavour enhancer within the ribonucleotides group (E626–E635).

International (JECFA)

The Joint FAO/WHO Expert Committee on Food Additives (JECFA) first evaluated disodium 5′-inosinate at its 18th meeting in 1974, assigning an acceptable daily intake (ADI) of "not specified" for inosinic acid and its salts based on toxicological assessments, thereby affirming its safety for use as a flavor enhancer at levels consistent with good manufacturing practices. JECFA has set a group ADI "not specified" for inosinic acid and its sodium, potassium and calcium salts, which is generally used when the overall toxicity is low and use is limited by good manufacturing practice.

9. Safety Considerations and Interactions

General Toxicological Profile

Studies examining the safety profile of disodium inosinate have not identified significant toxicological concerns at levels used in food. The compound is readily metabolized in the body to inosine and further to other nucleotide metabolites. Safety when used as a food additive has been approved by the U.S. Food and Drug Administration (FDA), European Food Safety Authority (EFSA), Joint FAO/WHO Expert Committee on Food Additives (JECFA), as well as other authorities.

Gout, Hyperuricemia, and Purine Metabolism

E631 (disodium inosinate) is a purine nucleotide that is ultimately metabolised to uric acid. For most people this is not an issue, but consumers with gout, recurrent kidney stones, hyperuricemia, or reduced kidney function may prefer to limit "purine boosters" in general. The degradation of IMP can lead to the formation of hypoxanthine and then xanthine, which are further metabolized into uric acid, linking it to disorders like gout when accumulated excessively.

The elevated serum uric acid level can be prevented by reducing the absorption of inosine and inosine-related purine compounds (such as hypoxanthine and inosine 5′-monophosphate), rather than adenosine and adenosine-related purine compounds.

Crucially, the dose context is essential: human data show that very high supplemental intakes of inosinate or related ribonucleotides can raise serum and urinary uric acid. Those dose levels are typically measured in grams per day and are far above what most people get from E631 as a flavour enhancer in foods. People who are sensitive to purines — often those with gout — are advised to avoid foods high in purines, including those containing disodium inosinate, as purines break down into uric acid in the body. Purines break down into uric acid, and high levels of uric acid can lead to the formation of crystals in joints, causing pain and inflammation associated with gout.

Sensitivity and Adverse Reactions

Some people may experience sensitivities to food additives, particularly those with asthma, allergies, or sensitivities to MSG. E631 can sometimes cause reactions similar to MSG-induced sensitivities, including headaches, chest pain, and flushing in some individuals, although these cases are rare. High consumption of flavor enhancers, including disodium inosinate, may lead to gastrointestinal discomfort in sensitive individuals. However, comprehensive studies specifically linking disodium inosinate to such effects in humans are limited.

Potential side effects are uncommon but may include rare allergic reactions or headaches in individuals sensitive to monosodium glutamate (MSG), though direct causation by disodium inosinate is not firmly established.

Lesch-Nyhan Syndrome and Purine Metabolism Disorders

Individuals with gout or certain genetic conditions affecting purine metabolism (such as Lesch-Nyhan syndrome) may wish to consult healthcare providers about purine-containing additives, as inosinate is a purine nucleotide. This is a factual consideration arising from the biochemical identity of IMP as a purine nucleotide and the metabolic defects in such conditions, not from clinical trials specifically examining IMP in these populations.

EFSA Feed Safety Evaluations (Indicative of Purity Standards)

EFSA's Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) assessed the safety of disodium 5′-inosinate (IMP) produced by Corynebacterium stationis KCCM 80235 as a sensory additive for all animal species. The applicant provided supplementary data which elucidated the genetic basis of the streptomycin resistance of the production strain and excluded the presence of its DNA in the final product. Therefore, the FEEDAP Panel concluded that IMP produced by C. stationis KCCM 80235 is safe for the target species, consumers, users and the environment. These assessments underscore that safety conclusions are dependent on purity of the final product and the absence of production-strain genetic material, matters relevant to manufacturing quality standards.

Summary of Evidence Limitations

Direct human clinical trials specifically examining disodium inosinate as an isolated dietary supplement are essentially absent from the literature. Its biochemical role in purine metabolism is thoroughly characterized from basic science. Its taste-enhancing properties are robustly supported by human psychophysical, neuroimaging, and receptor-level studies. Its safety as a food additive at typical use levels is supported by multiple international regulatory bodies. Evidence for benefits in immune function, muscle growth, or energy metabolism in humans comes from animal studies or general nucleotide nutrition literature and cannot be attributed specifically to supplemental IMP in human clinical settings.

References

• Ninomiya K. Umami the Fifth Basic Taste: History of Studies on Receptor Mechanisms and Role as a Food Flavor. BioMed Research International. 2015. PMC4515277.
• Ninomiya K. Glutamate: from discovery as a food flavor to role as a basic taste (umami). American Journal of Clinical Nutrition. 2009;90(3):719S–722S.
• Mouritsen OG, Styrbæk K. Science of umami taste: adaptation to gastronomic culture. Flavour. 2015;4:13.
• de Araujo IET, Kringelbach ML, Rolls ET, Hobden P. Representation of Umami Taste in the Human Brain. Journal of Neurophysiology. 2003;90(1):313–319.
• Chaudhari N, Pereira E, Roper SD. Taste receptors for umami: the case for multiple receptors. American Journal of Clinical Nutrition. 2009;90(3):738S–742S.
• Toda Y, et al. Two Distinct Determinants of Ligand Specificity in T1R1/T1R3 (the Umami Taste Receptor). PLoS ONE. 2013.
• Yasumatsu K, et al. Involvement of multiple taste receptors in umami taste: analysis of gustatory nerve responses in mGluR4 knockout mice. Journal of Physiology. 2015;593(4):1021–1034.
• Inosine-5′-monophosphate interacts with the TAS1R3 subunit to enhance sweet taste detection. PLOS ONE. 2025. PMC11872639.
• Hernandez P, et al. Dietary supplementation with inosine-5′-monophosphate improves the functional, energetic, and antioxidant status of liver and muscle growth in pigs. Scientific Reports. 2022;12(1):457.
• EFSA FEEDAP Panel. Safety of the feed additive consisting of disodium 5′-inosinate (IMP) produced by Corynebacterium stationis KCCM 80235 for all animal species. EFSA Journal. 2023;21(4):7958.
• EFSA FEEDAP Panel. Safety and efficacy of a feed additive consisting of disodium 5′-inosinate (IMP) produced by Corynebacterium stationis KCCM 80235 for all animal species. EFSA Journal. 2022;20(3):7153.
• EFSA FEEDAP Panel. Safety and efficacy of IMP (disodium 5′-inosinate) produced by fermentation with Corynebacterium stationis KCCM 80161 for all animal species. EFSA Journal. 2023;21(8):8139.
• U.S. Code of Federal Regulations. 21 CFR § 172.535 – Disodium inosinate. Electronic CFR.
• The Medical Biochemistry Page. Nucleotides: Biosynthesis and Catabolism.
• ScienceDirect Topics. Purine Nucleotide Cycle – Overview.
• Kuroda M, Miyamura N. The flavor-enhancing action of glutamate and its mechanism involving the notion of kokumi. npj Science of Food. 2023;7:3.
• Synergistic effect of combining umami substances enhances perceived saltiness. Food Research International. 2024.
• Eadditives. E631 – Disodium inosinate: Safety profile and regulatory overview. Updated 2025.
• Wikipedia. Disodium inosinate.
• Wikipedia. Umami.